Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Onconova Therapeutic (NQ: ONTX )

0.7300 +0.0100 (+1.39%)
Streaming Delayed Price Updated: 3:31 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 32,807
Open 0.7200
Bid (Size) 0.7100 (2)
Ask (Size) 0.7300 (3)
Prev. Close 0.7200
Today's Range 0.6961 - 0.7782
52wk Range 0.6200 - 2.040
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
Conference call and live webcast at 4:30 p.m. ET today 
From Onconova Therapeutics, Inc.
Via Globe NewsWire
Preview: Onconova Therapeutics's Earnings
 
Via Benzinga

Performance

YTD
+2.82%
+2.82%
1 Month
-15.82%
-15.82%
3 Month
+8.96%
+8.96%
6 Month
-33.03%
-33.03%
1 Year
-58.52%
-58.52%

More News

Read More
Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting
From Onconova Therapeutics, Inc.
Via Globe NewsWire
Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
From Onconova Therapeutics, Inc.
Via Globe NewsWire
Onconova Therapeutics's Return On Capital Employed Insights
Via Benzinga
Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertib’s Mechanisms of Action at the AACR Targeting RAS Conference
From Onconova Therapeutics, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Onconova Therapeutics Touts Additional Positive Data For Rigosertib Monotherapy In Skin Cancer Setting
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma
From Onconova Therapeutics, Inc.
Via Globe NewsWire
Onconova Therapeutics to Present at the 2023 Guggenheim Oncology Conference
From Onconova Therapeutics, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Onconova Therapeutics Announces Participation in the Channelchek Takeaway Series
From Onconova Therapeutics, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors
From Onconova Therapeutics, Inc.
Via Globe NewsWire
Onconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor Conference
From Onconova Therapeutics, Inc.
Via Globe NewsWire
Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference
From Onconova Therapeutics, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Fast Radius Shares Plunged Around 48%; Here Are 103 Biggest Movers From Yesterday
Via Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 67 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why PlayAGS Shares Are Trading Lower By Over 15%; Here Are 33 Stocks Moving Premarket
Via Benzinga
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update
From Onconova Therapeutics, Inc.
Via Globe NewsWire
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter Financial Results on November 14, 2022
From Onconova Therapeutics, Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.